

Global Acute Myeloid Leukemia Therapeutics Market - 2023-2033

<https://marketpublishers.com/r/GF23A57F125CEN.html>

Date: October 2025

Pages: 219

Price: US\$ 2,999.00 (Single User License)

ID: GF23A57F125CEN

Abstracts

The Global Acute Myeloid Leukemia Therapeutics Market was valued at US\$ 2.89 Billion in 2023 and is anticipated to reach US\$ 7.25 Billion by 2033, at a CAGR of 0.097 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Global Acute Myeloid Leukemia Therapeutics Market.

This report delivers a comprehensive overview of the Global Acute Myeloid Leukemia Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Global Acute Myeloid Leukemia Therapeutics Market. The Global Acute Myeloid Leukemia Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2023–2033.

Global Acute Myeloid Leukemia Therapeutics Market Scope:

Key Players

Genentech, Inc.

Major Highlights

This report delivers a comprehensive overview of the Global Acute Myeloid Leukemia Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Global Acute Myeloid Leukemia Therapeutics Market. The Global Acute Myeloid Leukemia Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2023–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned

to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. MARKET INTRODUCTION AND SCOPE

- 1.1. Objectives of the Report
- 1.2. Report Coverage & Definitions
- 1.3. Report Scope

2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS

- 2.1. Market Highlights and Strategic Takeaways
- 2.2. Key Trends and Future Projections
- 2.3. Snippet by Drug Class
- 2.4. Snippet by Disease Type
- 2.5. Snippet by Route of Administration
- 2.6. Snippet by Distribution Channel
- 2.7. Snippet by Region

3. DYNAMICS

- 3.1. Impacting Factors
 - 3.1.1. Drivers
 - 3.1.1.1. Growing Incidence of Acute Myeloid Leukemia
 - 3.1.1.2. Advancements in Targeted and Personalized Therapies
 - 3.1.2. Restraints
 - 3.1.2.1. Disease Heterogeneity
 - 3.1.2.2. High Treatment Costs
 - 3.1.3. Opportunity
 - 3.1.3.1. Advancements in CAR-T Cell Therapy
 - 3.1.3.2. Development of Combination Therapies

4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

- 4.1. Market Leaders and Pioneers
 - 4.1.1. Emerging Pioneers and Prominent Players
 - 4.1.2. Established Leaders with the Largest Marketing Brand
 - 4.1.3. Market Leaders with Established Products
- 4.2. Latest Developments and Breakthroughs
- 4.3. Regulatory and Reimbursement Landscape

- 4.3.1. North America
- 4.3.2. Europe
- 4.3.3. Asia Pacific
- 4.3.4. South America
- 4.3.5. Middle East & Africa
- 4.4. Porter's Five Forces Analysis
 - 4.4.1. Bargaining Power of Suppliers
 - 4.4.2. Bargaining Power of Buyers
 - 4.4.3. Threat of Substitutes
 - 4.4.4. Threat of New Entrants
 - 4.4.5. Competitive Rivalry
- 4.5. Patent Analysis
 - 4.5.1. Patent Expiry and Exclusivity
 - 4.5.2. Key Patent Holders
 - 4.5.3. Patent Litigations
 - 4.5.4. Licensing Opportunities
- 4.6. Unmet Needs and Gaps
- 4.7. Recommended Strategies for Market Entry and Expansion
- 4.8. Pricing Analysis and Price Dynamics
 - 4.8.1. Price Benchmarking vs Competitors
 - 4.8.2. Reimbursement Landscape
 - 4.8.3. Pricing Trends by Region or Segment
 - 4.8.4. Value-based Pricing Opportunities

5. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS

- 5.1. Introduction
 - 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
 - 5.1.2. Market Attractiveness Index, By Drug Class
- 5.2. Targeted Therapy *
 - 5.2.1. Introduction
 - 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
 - 5.2.3. FLT3 Inhibitors
 - 5.2.4. IDH Inhibitors
 - 5.2.5. Mylotarg
 - 5.2.6. BCL-2 Inhibitor
 - 5.2.7. Hedgehog Pathway Inhibitor
 - 5.2.8. Menin Inhibitor
- 5.3. Chemotherapy

- 5.3.1. Antimetabolites
 - 5.3.1.1. Cytarabine
 - 5.3.1.2. 5-Aza-cytidine
 - 5.3.1.3. Decitabine
 - 5.3.1.4. Fludarabine
 - 5.3.1.5. Others
- 5.3.2. Alkylating Agents
 - 5.3.2.1. Cyclophosphamide
 - 5.3.2.2. Melphalan
 - 5.3.2.3. Busulfan
 - 5.3.2.4. Treosulfan
 - 5.3.2.5. Others
- 5.3.3. Anthracycline Drugs
 - 5.3.3.1. Daunorubicin
 - 5.3.3.2. Idarubicin
 - 5.3.3.3. Doxorubicin
 - 5.3.3.4. Mitoxantrone
 - 5.3.3.5. Others
- 5.3.4. Others
- 5.4. Immunotherapy
 - 5.4.1. Bispecific Antibodies
 - 5.4.2. Antibody-drug Conjugates
 - 5.4.3. Immune Checkpoint Inhibitors
 - 5.4.4. Chimeric Antigen Receptor (CAR) T-cell Therapy
- 5.5. Others

6. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, BY DISEASE TYPE

- 6.1. Introduction
 - 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
 - 6.1.2. Market Attractiveness Index, By Disease Type
- 6.2. Myeloblastic Leukemia*
 - 6.2.1. Introduction
 - 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.3. Myelomonocytic Leukemia
- 6.4. Promyelocytic Leukemia
- 6.5. Monocytic Leukemia
- 6.6. Others

7. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION

7.1. Introduction

7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

7.1.2. Market Attractiveness Index, By Route of Administration

7.2. Parenteral*

7.2.1. Introduction

7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

7.3. Oral

8. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

8.1. Introduction

8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

8.1.2. Market Attractiveness Index, By Distribution Channel

8.2. Hospital Pharmacy*

8.2.1. Introduction

8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

8.3. Retail Pharmacy

8.4. Online Pharmacy

9. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES

10. INTRODUCTION

10.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

10.1.1. Market Attractiveness Index, By Region

10.2. North America

10.2.1. Introduction

10.2.2. Key Region-Specific Dynamics

10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type

10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

- 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 10.2.7.1. U.S.
 - 10.2.7.2. Canada
 - 10.2.7.3. Mexico
- 10.3. Europe
 - 10.3.1. Introduction
 - 10.3.2. Key Region-Specific Dynamics
 - 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
 - 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
 - 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
 - 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 10.3.7.1. Germany
 - 10.3.7.2. UK
 - 10.3.7.3. France
 - 10.3.7.4. Spain
 - 10.3.7.5. Italy
 - 10.3.7.6. Rest of Europe
- 10.4. Asia-Pacific
 - 10.4.1. Introduction
 - 10.4.2. Key Region-Specific Dynamics
 - 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
 - 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
 - 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
 - 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 10.4.7.1. China
 - 10.4.7.2. India
 - 10.4.7.3. Japan
 - 10.4.7.4. South Korea
 - 10.4.7.5. Rest of Asia-Pacific
- 10.5. South America
 - 10.5.1. Introduction
 - 10.5.2. Key Region-Specific Dynamics
 - 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
 - 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
 - 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.5.7.1. Brazil

10.5.7.2. Argentina

10.5.7.3. Rest of South America

10.6. Middle East and Africa

10.6.1. Introduction

10.6.2. Key Region-Specific Dynamics

10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type

10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. COMPETITIVE LANDSCAPE AND MARKET POSITIONING

12. COMPETITIVE OVERVIEW AND KEY MARKET PLAYERS

12.1. Market Share Analysis and Positioning Matrix

12.2. Strategic Partnerships, Mergers & Acquisitions

12.3. Key Developments in Product Portfolios and Innovations

12.4. Company Benchmarking

13. COMPANY PROFILES

13.1. Genentech, Inc.*

13.1.1. Company Overview

13.1.2. Product Portfolio

13.1.2.1. Product Description

13.1.2.2. Product Key Performance Indicators (KPIs)

14. FINANCIAL OVERVIEW

14.1. Company Revenue

14.1.1. Geographical Revenue Shares

14.1.1.1. Revenue Forecasts

14.1.2. Key Developments

14.1.2.1. Mergers & Acquisitions

14.1.2.2. Key Product Development Activities

14.1.2.3. Regulatory Approvals, etc.

14.1.3. SWOT Analysis

14.2. Servier Pharmaceuticals LLC.

14.3. Bristol-Myers Squibb Company.

14.4. Rigel Pharmaceuticals, Inc.

14.5. Novartis AG

14.6. Astellas Pharma Inc.

14.7. Daiichi Sankyo, Inc.

14.8. Jazz Pharmaceuticals plc

14.9. Pfizer Inc.

14.10. Teva Pharmaceutical Industries Ltd. (LIST NOT EXHAUSTIVE)

15. ASSUMPTIONS AND RESEARCH METHODOLOGY

15.1. Data Collection Methods

15.2. Data Triangulation

15.3. Forecasting Techniques

15.4. Data Verification and Validation

16. APPENDIX

16.1. About Us and Services

16.2. Contact Us

I would like to order

Product name: Global Acute Myeloid Leukemia Therapeutics Market - 2023-2033

Product link: <https://marketpublishers.com/r/GF23A57F125CEN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GF23A57F125CEN.html>